Daniel Barenboim, Parkinson's disease
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
Ben Foster has revealed the brutally honest chat he had with Phil Parkinson before sensationally joining Wrexham for a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback